About: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19
Creator	Azarova, Valeria Blinow, Andrew Dmitriev, Kirill Egorova, Alina Gordeev, Ivan Ilin, Alexey Ivachtchenko, Alexandre Ivashchenko, Andrey Karapetian, Ruben Kravchenko, Dmitry Lomakin, Nikita Merkulova, Elena Papazova, Natalia Pavlikova, Elena Savchuk, Nikolay Simakina, Elena Sitdekov, Tagir Smolyarchuk, Elena Tikhomolova, Elena Vostokova, Natalia Yakubova, Elena
source	MedRxiv
abstract	In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1101/2020.07.26.20154724
has license	medrxiv
sha1sum (hex)	041faf88e7e39c88383ea6db6defd73ce2d67cf0
schema:url	https://doi.org/10.1101/2020.07.26.20154724
resource representing a document's title	Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19
resource representing a document's body	covid:041faf88e7e39c88383ea6db6defd73ce2d67cf0#body_text
is schema:about of	named entity 'clinical trials' named entity 'preprint' named entity 'COVID-19' named entity 'Phase II' named entity 'oral drug' named entity 'preprint' named entity 'liver transaminase' named entity 'coronavirus infection' named entity 'vomiting' named entity 'PCR tests' named entity 'medRxiv' named entity 'COVID-19' named entity 'Phase II' named entity 'clinical study' named entity 'CC-BY-ND' named entity 'R&D' named entity 'medRxiv' named entity 'intent-to-treat' named entity 'preprint' named entity 'COVID' named entity 'medRxiv' named entity 'fast-track' named entity 'ITT' named entity 'COVID' named entity 'COVID' named entity 'preprint' named entity 'medRxiv' named entity 'pharmaceutical industry' named entity 'antiviral activity' named entity 'preprint' named entity 'Dose-dependent' named entity 'vital signs' named entity 'control group' named entity 'antibiotics' named entity 'chronic conditions' named entity 'medRxiv' named entity 'Avigan' named entity 'Japan' named entity 'PCR' named entity 'nausea' named entity 'AST' named entity 'adverse drug reactions' named entity 'pneumonia' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'Russian Ministry of Health' named entity 'preprint' named entity 'COVID' named entity 'second-line treatment' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'informed consent' named entity 'diarrhea' named entity 'favipiravir' named entity 'mechanical ventilation' named entity 'influenza outbreaks' named entity 'ICU' named entity 'preprint' named entity 'health professionals' named entity 'preprint' named entity 'preprint' named entity 'CC-BY-ND' named entity 'treatment group' named entity 'fast-track'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software